6 April 2020

�

�

RECKITT BENCKISER GROUP PLC

("RB" or the "Company")

�

2019 Annual Report and Notice of the 2020 Annual General Meeting

�

�

RB confirms that the following documents are today published and are available on its website, www.rb.com:

�

������ Annual Report and Financial Statements for the year ended 31 December 2019 ("2019 Annual Report")

�

������ Notice of the Annual General Meeting 2020 to be held on 12 May 2020 ("2020 AGM Notice")

�

In compliance with LR 9.6.1, the following documents have also been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism:

�

������ 2019 Annual Report

������ 2020 AGM Notice

������ Form of Proxy for the 2020 Annual General Meeting

�

In compliance with rule 6.3.5R of the Disclosure Guidance and Transparency Rules the documents can also be downloaded in pdf format from the Company's website at www.rb.com, and will be posted to shareholders who have elected to receive paper communications on 6 April 2020.

�

The Company's 2020 Annual General Meeting will be held at 3.00pm on Tuesday 12 May 2020 at 103-105�Bath Road Slough, Berkshire, SL1 3UH.�In light of the evolving situation regarding the outbreak of the COVID-19 virus, on 23 March 2020 the UK Government instructed that people should not leave their homes, except in very limited circumstances. �We therefore strongly recommend that shareholders refrain from attending the AGM in person. Shareholders and their proxies are asked, and strongly encouraged, to utilise the option to vote by proxy in advance of the AGM without attending in person. Details of how to vote by proxy are set out in the 2020 AGM Notice.

�

It is our current intention to live-stream the AGM so that Shareholders will be able to follow the meeting remotely. However, this will be kept under review and subject to the Government guidance in place at the time of the AGM. Details of the web-access link to the meeting will be available at www.rb.com/investors/your-shareholding/agm/. Please note that the web facility will be provided for information purposes only and will not be a formal part of the meeting.�

Shareholders may submit written questions in advance of the AGM if they wish.� If you have any such questions, please send them either by post to the Company's head office at Reckitt Benckiser Group plc, 103-105 Bath Road, Slough SL1 3UH or by e-mail to�[email protected]��to be received no later than 5 May 2020, the fifth business day preceding the date of the AGM.� Please ensure that your shareholder details are included with your communication.� We will endeavour to answer a representative selection of any questions received in advance at the AGM.

�

A condensed set of the Company's financial statements and information on important events that have occurred during the financial year and their impact on the financial statements were included in RB's preliminary announcement of annual results released on 27 February 2020. That information, together with the information set out in the Appendix below, which is extracted from the 2019 Annual Report, constitutes the material required for the purposes of compliance with DTR 6.3.5R. This announcement is not a substitute for reading the full 2019 Annual Report. Page numbers in the extracted information below refer to page numbers in the 2019 Annual Report.

�

For further Information:
Rupert Bondy

Company Secretary

Tel +44 (0) 1753 217 800

�

John Dawson

SVP, Investor Relations

Tel. +44 (0) 1753 217 800

�

Reckitt Benckiser Group plc's LEI code is 5493003JFSMOJG48V108

�

�

About RB

RB* is driven by its purpose to protect, heal and nurture in a relentless pursuit of a cleaner, healthier world. We fight to make�access to the highest-quality hygiene, wellness and nourishment a right, not a privilege, for everyone.

RB is proud to have a stable of trusted household brands found in households in more than 190 countries. These include Enfamil, Nutramigen, Nurofen, Strepsils, Gaviscon, Mucinex, Durex, Scholl, Clearasil, Lysol, Dettol, Veet, Harpic, Cillit Bang, Mortein, Finish, Vanish, Calgon, Woolite, Air Wick and more.� 20 million RB products a day are bought by consumers globally.

RB's passion to put consumers and people first, to seek out new opportunities, to strive for excellence in all that we do, and to build shared success with all our partners, while doing the right thing, always�is what guides the work of our 40,000+ diverse and talented colleagues worldwide.

For more information visit�www.rb.com

*RB is the trading name of the Reckitt Benckiser group of companies

�

Cautionary note concerning forward-looking statements

�

This announcement and the Annual Report and Financial Statements contains statements with respect to the financial condition, results of operations and business of RB (the 'Group') and certain of the plans and objectives of the Group that are forward-looking statements. Words such as 'intends', 'targets', or the negative of these terms and other similar expressions of future performance or results, and their negatives, are intended to identify such forward-looking statements. In particular, all statements that express forecasts, expectations and projections with respect to future matters, including targets for Net Revenue, operating margin and cost efficiency, are forward looking statements. Such statements are not historical facts, nor are they guarantees of future performance.

�

By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements, including many factors outside the Group's control. Among other risks and uncertainties, the material or principal factors which could cause actual results to differ materially are: the general economic, business, political and social conditions in the key markets in which the Group operates; the ability of the Group to manage regulatory, tax and legal matters, including changes thereto; the reliability of the Group's technological infrastructure or that of third parties on which the Group relies; interruptions in the Group's supply chain and disruptions to its production facilities; the reputation of the Group's global brands; and the recruitment and retention of key management.

�

These forward-looking statements speak only as of the date of this announcement. Except as required by any applicable law or regulation, RB expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Group's expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

�

Any information contained in the 2019 Annual Report and Financial Statements on the price at which shares or other securities in Reckitt Benckiser Group plc have been bought or sold in the past, or on the yield on such shares or other securities, should not be relied upon as a guide to future performance.

�

�

�

�

�

APPENDIX

The primary purpose of this announcement is to inform the market about the publication of RB's 2019 Annual Report and 2020 AGM Notice.

The information below, which is extracted from the 2019 Annual Report, is included solely for the purpose of complying with DTR 6.3.5R and the requirements it imposes on issuers as to how to make public annual financial reports. It should be read in conjunction with the preliminary announcement released on 27 February 2020. Together these constitute the material required by DTR 6.3.5R to be communicated in unedited full text through a Regulatory Information Service. This material is not a substitute for reading the full 2019 Annual Report.

Page and note references in the text below relate to pages and notes in the 2019 Annual Report.

�

(i)�� OUR APPROACH TO INTEGRATED RISK MANAGEMENT AT RB (pages 64 to 77)

�

Risk management occurs at different levels in RB with identification and assessment performed at the functional, business unit, corporate and Group levels to provide both a 'top-down' and 'bottom-up' three-dimensional view of risk and is implemented as follows:

�

�

Our approach to principal and emerging risk assessment

The Group principal and emerging risk assessment is an integral part of the integrated risk management framework above, identifying the principal and emerging risks with the greatest potential to impact the Group. The assessment is completed annually in advance of the business unit and corporate strategic planning process as follows:

�

�

�

�

Our principal and emerging risks, as at 31 December 2019

�

Key to principal risks

�

�

�

�

�

�

�

*See Viability Statement on page 77

�

�

�

�

�

*See Viability Statement on page 77

�

�

�

�

*See Viability Statement on page 77

�

�

�

Emerging risks

�

The implementation of an effective risk management framework within an organisation remains a cornerstone of the corporate governance expectations contained within the 2018 revisions to the UK Corporate Governance Code.

�

A new requirement (for accounting periods starting 1 January 2019 or later) is described in Provision 28 as follows: for management to carry out a robust assessment of emerging risks as well as principal risks and explain in the Annual Report what procedures are in place to identify emerging risks, including how these risks are being managed or mitigated. We have defined an emerging risk as an event that has the potential to significantly impact RB's financial position, competitiveness and reputation, specifically;

����� When the nature and value of the impact is not yet fully known or understood, giving the emerging nature of the risk; and/or

����� With an increasing impact and probability over a longer time horizon (i.e. 5+ years)

�

2019 Emerging risks

�

�

COVID-19

We are closely monitoring the outbreak of COVID-19, and how it will affect our operations in key markets. While the full scale of the disruption is still evolving, immediate impacts may include shortages of raw and pack materials, potential closure of supply sites and restrictions on the movement of people. Planning is underway in affected countries to ensure we are prepared for the impact of the outbreak on our people and supply chains, and appropriate contingencies put in place.

�

As an organisation, we are taking whatever steps we can to minimise any risk that we may contribute to the virus spreading.
These include restrictions on travel, providing up-to-date resources to all employees and guidance on working remotely where required.

�

1. Digital Capability

�

The risk: We lack strategic direction and investment in capability to succeed in an increasingly digital marketplace.

�

Potential impact

While we have made significant investment to build our e-commerce capability, continued investment in developing and executing our digital strategy is critical in order to enhance our digital solutions, protect market share and drive sustained growth across priority channels.

�

Mitigation

As we begin the next phase of transformation, understanding how we can both continue to build digital capability and increase the quality and efficiency of core processes through digital solutions, is a priority. We also plan to further develop our digital marketing and CRM capability. Chief among these projects will be the continued development of the Product Lifecycle Management (PLM) system, and enhanced integration of resource planning and reporting systems.

�

2. Change Execution (Health)

�

The risk: We do not execute the required changes to create an effective operating model and deliver the required improved performance across the business.

�

Potential impact

Failure to effectively execute the key change programs required across the Health business may result in cost overruns and inefficient use of resources, loss of key talent and distract us from future growth priorities.

�

Mitigation

By focusing on stabilising brand performance, simplifying the operating model and increasing productivity, we are working to return Health to outperformance. A number of internal initiatives are underway to drive this, with appropriate oversight and governance from the Health leadership team.

�

3. China

�

The risk: Risk of economic uncertainty in China, changing regulations and changes in current or new partners impacting growth and business performance.

�

Potential impact

China is a critical market increasingly characterised by economic uncertainty. This includes trade conflicts between China and other major trading partners and regional tensions. The behaviours of Chinese consumers are also changing alongside other domestic economic factors that, all combined, have the potential to impact how�we manufacture and supply this market.

�

Mitigation

We maintain a strong network in China so that we can understand both international and domestic economic developments that may impact our footprint. This includes active engagement with industry associations and regulators, external affairs capability and collaborative partnerships with government agencies.

�

Our China based regulatory intelligence teams provide insight on any changes in regulation that may impact us, and we work closely with local industry to ensure we are working within government set parameters.

�

Our global operations are subject to appropriate forex hedging that allows us to maintain accurate balance sheet forecasting and minimise any unwanted exposures.

�

�

Viability Statement

The Board conducted a Viability Review covering a five-year period. This period was selected as it is the period covered in the Group's long-term forecasting process, which covers the introduction to market of the current new product pipeline. The five-year Viability Review first looks at the Group's ability to continue in operation if it performs in line with the Group forecast. This assumes that normal market conditions continue and current trends remain.

�

The evaluation takes into account the Group's cash flow, historical Group planning accuracy, available banking facilities and interest cover ratios in connection with financial covenants. The analysis concluded that if RB performs in line with forecasts it would have sufficient funds to trade, settle its liabilities as they fall due, and remain compliant with financial covenants.

�

The analysis goes on to consider the viability of the business should adverse unexpected events arise. To illustrate this, a sensitised view of the Group forecast was produced. The adverse assumptions are based primarily upon the realisation of key Group principal risks, which have the most relevant potential impact on viability (see risks marked '*' on pages 64 to 76). The adverse assumptions also took account of the potential impact of COVID-19 on the Group's production sites, supply chains, distribution channels and customers.

�

The sensitivity assigns each adverse assumption an estimated annual monetary value and estimates the impact on interest cover ratios and headroom over available borrowing facilities. The analysis concludes that even with the occurrence of key unexpected scenarios, RB would still have sufficient funds to trade, settle its liabilities as they fall due, and remain compliant with financial covenants.

�

The Board has further considered the occurrence of a Black Swan event: an event with sufficient potential impact to risk the future of RB as a strong and independent business operating in its chosen markets. The occurrence of a major issue could result in significant reputational impact, a substantial share price fall, significant loss of consumer confidence, and the inability to retain and recruit quality people. Such an event could have an impact on the viability of the business.

�

As there are a number of mitigating controls in place across
the business, the occurrence of a Black Swan event is considered sufficiently unlikely that it has not been factored into the
sensitivity analysis.

�

As a result of the Viability Review, the Board has a reasonable expectation that the Group will be able to continue in operation and meet its liabilities as they fall due over the five-year period covered in the Viability Review.

�

�

(ii)� RELATED PARTY TRANSACTIONS (pages 200 and 211)

�

NOTE 26 RELATED PARTY TRANSACTIONS

Put and call options with non-controlling Shareholders

Within the Health Operating Segment, there are symmetrical put and call options existing over the non-controlling shareholdings in RB & Manon Business Co. Ltd, RB & Manon Business Limited and RB (China Trading) Limited. In 2018, the parties agreed to extend these options to 31 December 2023. In the event that the options are not exercised in accordance with the agreement, they are automatically extended for a further six years.

�

Within the Hygiene Home Operating Segment, there are symmetrical put and call options existing over the non-controlling shareholdings in RB (Hygiene Home) HK Limited, RB & Manon Hygiene Home (HK) Limited and RB & Manon Hygiene Home (Shanghai) Limited. These options were first agreed in 2019 and are currently due to expire on 31 December 2024. In the event that the options are not exercised in accordance with the agreement, they are automatically extended for a further six years.

�

At 31 December 2019, the present value of these put option liabilities was �135 million (2018: �148 million).

�

Other

The Group has related party relationships with its directors and key management personnel (Note 5).

�

PARENT COMPANY NOTE 9 RELATED PARTY TRANSACTIONS

There were no transactions with related parties other than wholly owned companies within the Group.

�

(iii) STATEMENT OF DIRECTORS' RESPONSIBILITIES (page 141)

The Directors are responsible for preparing the Annual Report and the Group and Parent Company Financial Statements in accordance with applicable law and regulations.

�

Company law requires the Directors to prepare Group and Parent Company Financial Statements for each financial year. Under that law they are required to prepare the Group Financial Statements in accordance with International Financial Reporting Standards as adopted by the European Union (IFRSs as adopted by the EU) and applicable law and have elected to prepare the Parent Company Financial Statements in accordance with UK accounting standards, including FRS 102, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

�

Under company law the Directors must not approve the Financial Statements unless they are satisfied that they give a true and fair view of the state of affairs of the Group and Parent Company and of their profit or loss for that period. In preparing each of the Group and Parent Company Financial Statements, the Directors are required to:

������ select suitable accounting policies and then apply them consistently;

������ make judgements and estimates that are reasonable, relevant, reliable and prudent;

������ for the Group Financial Statements, state whether they have been prepared in accordance with IFRSs as adopted by the EU and IFRSs as issued by the International Accounting Standards Board (IASB) and due to a requirement of the US SEC, state they have been prepared in accordance with IFRSs as issued by the International Accounting Standards Board (IASB);

������ for the Parent Company Financial Statements, state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the parent Company Financial Statements;

������ assess the Group and Parent Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern; and

������ use the going concern basis of accounting unless they either intend to liquidate the Group or the Parent Company or to cease operations, or have no realistic alternative but to do so.

�

The Directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Parent Company's transactions and disclose with reasonable accuracy at any time the financial position of the Parent Company and enable them to ensure that its Financial Statements comply with the Companies Act 2006. They are responsible for such internal control as they determine is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error, and have general responsibility for taking such steps as are reasonably open to them to safeguard the assets of the Group and to prevent and detect fraud and other irregularities.

�

Under applicable law and regulations, the Directors are also responsible for preparing a Strategic Report, Directors' Report, Directors' Remuneration Report and Corporate Governance Statement that comply with that law and those regulations.

�

The Directors are responsible for the maintenance and integrity of the corporate and financial information included on the Company's website. Legislation in the UK governing the preparation and dissemination of Financial Statements may differ from legislation in other jurisdictions.

�

Responsibility statement of the Directors in respect of the annual financial report

We confirm that to the best of our knowledge:

������ the Financial Statements, prepared in accordance with the applicable set of accounting standards, give a true and fair view of the assets, liabilities, financial position and profit or loss of the Company and the undertakings included in the consolidation taken as a whole; and

������ the Annual Report and Financial Statements includes a fair review of the development and performance of the business and the position of the issuer and the undertakings included in the consolidation taken as a whole, together with a description
of the principal risks and uncertainties that they face.

�

We consider the Annual Report and Financial Statements, taken as a whole, is fair, balanced and understandable and provides the information necessary for Shareholders to assess the Group's position and performance, business model and strategy.

�

___________________________________